Skip to content

A clinical study to compare the effect Madhyama panchamoola churna Madhyama panchamoola sadita ghrita and tab.Paternia in increasing sperm count in the patients of oligospermia.

Analytical and Clinical evaluation of Madhyama panchamoola for Shukrala karma in Ksheenashukra w.s.r to Oligospermia - MSKO

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/12/022322
Enrollment
100
Registered
2019-12-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N461- Oligospermia

Interventions

Intervention1: Madhyama panchamoola sadita ghrita, Madhyama panchamoola churna: Madhyama panchamoola sadita ghrita 15ml twice daily before food with ksheera for 75 days Madhyama panchamoola churna 6g

Sponsors

Government Ayurveda Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Sperm count less than 15 million per ml, Sign and symptoms of Ksheenashukra like Dourbalya, Mukashosha, Pandutva and chirat praseka etc, Married men with in age group between 21 to 45 years Subjects are selected as per the profarma prepared for the purpose.

Exclusion criteria

Exclusion criteria: Patients with Azospermia and Aspermia, Age below 21 or above 45 years, Patient with known cases of Genetic defects, diagnosed cases of Varicocele, Infections,Endocrinological diseses, Systemic diseases and STDs

Design outcomes

Primary

MeasureTime frame
Sperm count more than 15 million per ml Timepoint: 30 th day

Secondary

MeasureTime frame
changes in FSH,LH and Testosterone hormones and international index of erectile function scores Timepoint: 75th 90 th days

Countries

India

Contacts

Public ContactDr Nagendra chary M

Government Ayurveda Medical College

drlalithabr62@gmail.com9343707722

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026